Economics, Pharmaceutical
"Economics, Pharmaceutical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Economic aspects of the fields of pharmacy and pharmacology as they apply to the development and study of medical economics in rational drug therapy and the impact of pharmaceuticals on the cost of medical care. Pharmaceutical economics also includes the economic considerations of the pharmaceutical care delivery system and in drug prescribing, particularly of cost-benefit values. (From J Res Pharm Econ 1989;1(1); PharmacoEcon 1992;1(1))
| Descriptor ID |
D017850
|
| MeSH Number(s) |
N03.219.390
|
| Concept/Terms |
Pharmacy Economics- Pharmacy Economics
- Economic, Pharmacy
- Economics, Pharmacy
- Pharmacy Economic
|
Below are MeSH descriptors whose meaning is more general than "Economics, Pharmaceutical".
Below are MeSH descriptors whose meaning is more specific than "Economics, Pharmaceutical".
This graph shows the total number of publications written about "Economics, Pharmaceutical" by people in this website by year, and whether "Economics, Pharmaceutical" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1999 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 2 | 4 | 6 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Economics, Pharmaceutical" by people in Profiles.
-
Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer. Pharmacoeconomics. 2014 Oct; 32(10):1005-13.
-
Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther. 2012 Apr; 34(4):788-802.e3.
-
Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III. Value Health. 2009 Nov-Dec; 12(8):1062-73.
-
Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I. Value Health. 2009 Nov-Dec; 12(8):1044-52.
-
Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II. Value Health. 2009 Nov-Dec; 12(8):1053-61.
-
The OMERACT Initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology. J Rheumatol. 2009 Sep; 36(9):2045-9.
-
Is it time for reporting guidelines for calibration methods? Pharmacoeconomics. 2009; 27(7):529-31.
-
Information technology facilitates cost-effectiveness analysis in developing countries: an observational study of breast cancer chemotherapy in Taiwan. Pharmacoeconomics. 2009; 27(11):947-61.
-
Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008 Nov 05; 100(21):1542-51.
-
Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care. 2008 Apr; 14(3 Suppl):S102-6.